QZ

Qiuyang Zhang

The Affiliated Eye Hospital, Nanjing Medical University

Affiliated withNanjing Medical University

Research Area

Biography

Qiuyang Zhang has not added Biography.
If you are Qiuyang Zhang and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
$Novel Micropulse Transscleral Cyclophotocoagulation System for Clinical Treatment of Refractory Glaucoma$ Publication title	2025

Other Publications

Article	Year
Osthole: A Traditional Chinese Medicine for Ocular Anti-Angiogenic Therapy. Ophthalmic research\| PubMed ID: 31945770	2020
SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo. Molecular medicine reports\| PubMed ID: 32323773	2020
Suppression of pathological ocular neovascularization by a small molecule, SU1498. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie\| PubMed ID: 32454287	2020
Role of METTL3-Dependent N-Methyladenosine mRNA Modification in the Promotion of Angiogenesis. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 32755566	2020
A small molecular multi-targeting tyrosine kinase inhibitor, anlotinib, inhibits pathological ocular neovascularization. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie\| PubMed ID: 33740528	2021
CircRNA expression profile and functional analysis in retinal ischemia-reperfusion injury. Genomics\| PubMed ID: 33771636	2021
METTL3-mediated -methyladenosine modification governs pericyte dysfunction during diabetes-induced retinal vascular complication. Theranostics\| PubMed ID: 34987645	2022
Targeting circular RNA-MET for anti-angiogenesis treatment via inhibiting endothelial tip cell specialization. Molecular therapy : the journal of the American Society of Gene Therapy\| PubMed ID: 34999209	2022
tRNA-derived fragment tRF-1001: A novel anti-angiogenic factor in pathological ocular angiogenesis. Molecular therapy. Nucleic acids\| PubMed ID: 36381574	2022
Suppression of Pathological Ocular Neovascularization by a Small Molecular Multi-Targeting Kinase Inhibitor, DCZ19903. Translational vision science & technology\| PubMed ID: 36484641	2022
DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization. Scientific reports\| PubMed ID: 36513701	2022
Microglia-endothelial cross-talk regulates diabetes-induced retinal vascular dysfunction through remodeling inflammatory microenvironment. iScience\| PubMed ID: 38414848	2024
Non-Coding RNAs: Novel Regulators of Macrophage Homeostasis in Ocular Vascular Diseases. Biomolecules\| PubMed ID: 38540748	2024
Olink Profiling of Aqueous Humor Identifies Novel Biomarkers for Wet Age-Related Macular Degeneration. Journal of proteome research\| PubMed ID: 38902972	2024
Targeted Proteomics Profiling for Biomarker Discovery in Glaucoma Using the Olink Proteomics Platform. Journal of proteome research\| PubMed ID: 39319515	2024
N 6-Methyladenosine Demethylase FTO Controls Macrophage Homeostasis in Diabetic Vasculopathy. Diabetes\| PubMed ID: 39446524	2025
Macrophage metabolic reprogramming ameliorates diabetes-induced microvascular dysfunction. Redox biology\| PubMed ID: 39647239	2025
Exosome-loading miR-205: a two-pronged approach to ocular neovascularization therapy. Journal of nanobiotechnology\| PubMed ID: 39844301	2025
Olink proteomics profiling reveals metabolism-related protein biomarkers in diabetic retinopathy. Experimental eye research\| PubMed ID: 40543798	2025